Pacira Pharmaceuticals Insider Gary Patou Unloads 20,000 Shares (PCRX)
Pacira Pharmaceuticals (NASDAQ:PCRX) Insider Gary Patou unloaded 20,000 shares of the stock on the open market in a transaction dated Tuesday, October 1st. The shares were sold at an average price of $48.92, for a total value of $978,400.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
Shares of Pacira Pharmaceuticals (NASDAQ:PCRX) traded up 2.15% during mid-day trading on Friday, hitting $53.77. 488,958 shares of the company’s stock traded hands. Pacira Pharmaceuticals has a 52-week low of $15.07 and a 52-week high of $54.11. The stock has a 50-day moving average of $40.82 and a 200-day moving average of $32.98. The company’s market cap is $1.791 billion.
PCRX has been the subject of a number of recent research reports. Analysts at Wedbush raised their price target on shares of Pacira Pharmaceuticals (NASDAQ:PCRX) from $43.00 to $59.00 in a research note to investors on Thursday. They now have an “outperform” rating on the stock. Separately, analysts at Brean Capital raised their price target on shares of Pacira Pharmaceuticals (NASDAQ:PCRX) from $44.00 to $59.00 in a research note to investors on Thursday. They now have a “buy” rating on the stock. Finally, analysts at Jefferies Group raised their EPS on shares of Pacira Pharmaceuticals (NASDAQ:PCRX) in a research note to investors on Tuesday, October 1st. They now have a “buy” rating and a $58.00 price target on the stock. They previously had a $44.00 price target on the stock. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $51.40.
Pacira Pharmaceuticals, Inc is a United States-based pharmaceutical company. The Company develops non-opioid products for postsurgical pain control.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.